阿普斯特(MPRILA)能有效治病吗？

Introduction: Apremilast is classified as a small molecule phosphodiesterase 4 (PDE4) inhibitor. The FDA approved the drug for the treatment of adult patients with plaque psoriasis who are suitable for phototherapy or systemic therapy, and for the treatment of psoriatic arthritis in adults with moderately to severely active psoriasis.

With the continuous development of generic drug technology, generic versions of Apremilast (MPRILA) have gradually entered the market. So, can the generic version of Apremilast (MPRILA) also be effective in treating diseases? This article will discuss the effectiveness of the generic version of Apremilast (MPRILA) and its clinical treatment effect.

Can the generic version of Apremilast (MPRILA) also effectively treat diseases?

As a replica of the original drug, the chemical composition and pharmacological effects of the generic version are basically the same as those of the original drug. The generic version of Apremilast (MPRILA) should have basically the same curative effect as the original drug. However, the efficacy of generic drugs is also affected by many factors such as manufacturing processes and quality control. Therefore, to determine whether the generic version of Apremilast (MPRILA) can also effectively treat diseases, it still needs to be verified through clinical trials and actual use.

If there is no significant difference in bioequivalence between the generic drug and the original drug, the generic drug can be considered to have basically the same efficacy and safety as the original drug.

Clinical therapeutic effects of Apremilast (MPRILA)

Apremilast (MPRILA), as a phosphodiesterase 4 (PDE4) inhibitor, increases intracellular cyclic adenosine monophosphate levels by inhibiting the activity of PDE4, thereby regulating the expression of tumor necrosis factor and other inflammatory cytokines, and inhibiting inflammatory responses. This mechanism makes Apremilast (MPRILA) excellent in the treatment of autoimmune diseases such as psoriasis and psoriatic arthritis.

Clinical trials have shown that Apremilast has significant efficacy in the treatment of moderate to severe plaque psoriasis. After the patient received treatment, his Psoriasis Area and Severity Index (PASI) score decreased significantly and his skin symptoms improved significantly. In addition, Apremilast can significantly improve patients' quality of life and reduce discomfort symptoms such as itching and pain caused by psoriasis.

Contraindications of Apremilast (MPRILA)

Apremilast treatment is contraindicated in subjects with confirmed allergy to Apremilast or any component of this pharmaceutical preparation. Reproductive studies in animal models during pregnancy indicate that treatment with Apremilast increases the risk of fetal miscarriage. To date, no reproductive studies have been reported on the use of apremilast during human pregnancy, and pregnancy planning and prevention are recommended for women of childbearing potential.

It is recommended that women of childbearing potential use contraception during treatment with Apremilast. This drug is contraindicated in lactating women. It is also not advisable to receive live vaccines while receiving Apremilast, as it may reduce the therapeutic effect of the vaccine.